Background
==========

Clear cell carcinoma prevailingly occurs in the ovary \[[@b1-medscimonit-26-e919789]\] and kidney \[[@b2-medscimonit-26-e919789]\], however, it has been rarely reported in additional locations like the lungs \[[@b3-medscimonit-26-e919789]\], liver \[[@b4-medscimonit-26-e919789]\]. Primary clear cell carcinoma of the liver (PCCCL) is an uncommon pathological subtype of primary hepatocellular carcinoma (HCC), with insufficient comprehension of its clinicopathological characteristics and prognostic factors on account of merely few case reports or clinical cohort studies from small, single institution. PCCCL is commonly endowed with a low-grade malignancy and distinct histopathological profile \[[@b5-medscimonit-26-e919789]\]. It is pathologically characterized by prominent cytoplasmic accumulation of abundant glycogen or/and lipid that are dissolved during hematoxylin and eosin staining, thereby merely showing a clear cytoplasm \[[@b6-medscimonit-26-e919789]\]. PCCCL can develop at any age, with a peak incidence in male patients aging from 50 to 60 years old \[[@b4-medscimonit-26-e919789]\].

The most pressing risk factor for PCCCL is hepatitis C virus (HCV) infection, while PCCCL is not significantly correlative with alcoholism, hepatitis B virus infection, nonalcoholic steatohepatitis, hemochromatosis, and autoimmune liver disease \[[@b7-medscimonit-26-e919789]\]. The onset and clinical manifestations of PCCCL basically resemble those of HCC, characterized by certain unspecific symptoms, such as right upper quadrant pain, fatigue, and anorexia and generally concomitant with medical history of viral hepatitis and cirrhosis as well as elevated alpha-fetoprotein (AFP) levels. Therefore, early detection of PCCCL is difficult. Frequently, representative imaging characteristics of PCCCL are inchoate enhancement and fast washout of contrast medium on dynamic contrast scans, and existence of portal vein thrombus or phyma rupture \[[@b8-medscimonit-26-e919789]\].

Notably, studies have shown that PCCCL cases account for 0.4% to 37% of all HCCs, and these variable reports are primarily attributable to the inconsistency of pathologically diagnostic criteria for such tumor. More precisely, Lai et al. indicated that PCCCL could be diagnosed even though clear cells proportion was less than 30% \[[@b9-medscimonit-26-e919789]\]. In contrast, another study implicated that the definite diagnosis of PCCCL should be made under the condition that clear cells proportion represented over 30% \[[@b10-medscimonit-26-e919789]\]. The majority of physicians support that when clear cells occupy more than 50% through histological examination, it should be diagnosed as PCCCL \[[@b11-medscimonit-26-e919789]--[@b14-medscimonit-26-e919789]\]. And PCCCL merely accounts for 2.2--6.7% of all HCC in a large proportion of studies through utilizing this criterion \[[@b11-medscimonit-26-e919789],[@b15-medscimonit-26-e919789]\]. Indeed, Liu et al. reported that PCCCL merely occupied approximately 3.5% of primary HCC in their hospital \[[@b15-medscimonit-26-e919789]\]. Notably, PCCCL is stuck in a diagnostic predicament without the assistance of immunohistochemical staining, as cytokeratin profiling and evidence of immunoreactivity for AFP and epithelial membrane antigen (EMA) are presumably a beneficial criterion to differentiate PCCCL from metastatic clear cell carcinomas originated from adrenals, kidneys, ovaries, and additional tissues \[[@b16-medscimonit-26-e919789]\]. To date, surgical intervention is considered to be the optimal treatment modality for PCCCL. Most patients receiving surgical resection have a desirable curative effect and a promising long-term survival rate.

In accordance with the World Health Organization (WHO) International Classification of Diseases for Oncology, version 3 (ICD-O.3), PCCCL is recognized as one of the subtypes of primary HCC \[[@b17-medscimonit-26-e919789]\]. Because of its rarity, a large number of previous studies are centralized case reports or series or small cohort study from single institutions. Currently, its clinicopathological and prognostic features are not fully elucidated in the literature. Therefore, in our study, we retrospectively analyzed the demographic and clinicopathological information of 419 PCCCL patients registered in the Surveillance, Epidemiology and End Results (SEER) database between 1988 and 2015, which was instrumental in unveiling the prognostic factors influencing its survival.

Material and Methods
====================

Data source
-----------

Original information was excavated from the SEER database supported by the National Cancer Institute. The SEER program was comprised of 18 population-based cancer registries, covering \~28% of the US population. The SEER program is publicly accessible, which merely contains anonymized patient information. Thus, our study was exempt from the ethical review or the patient consent.

Patient enrollment
------------------

We incorporated all patients with the histologically diagnosed 8174/3 (hepatocellular carcinoma, clear cell type) based on the ICD-O-3/WHO 2008, ranging from 1988 to 2015 registered in the SEER database. Only patients \>18 years of age with PCCCL as their "one primary only" tumor were incorporated in the study dataset. Moreover, records with insufficient information concerning survival, histology, or staging data (including tumor size and extension) were eliminated. We stratified total cohort based upon both demographic and clinicopathological characteristics such as age at diagnosis, gender, ethnicity, marital status at diagnosis, pathological differentiation grade, AFP interpretation, fibrosis, tumor size, lymph node invasion, distant metastases, SEER summary stage, TNM stage, and whether surgery, chemotherapy or radiotherapy were received.

Statistical analysis
--------------------

We downloaded all the data from SEER\*Stat Software version 8.3.5 (National Cancer Institute, Bethesda, MD, USA). Statistical analysis was implemented by the software SPSS 22.0 (IBM Corporation, Armonk, NY, USA). A Student's *t-*test was applied to make a contrast of continuous variables and a chi-squared test was utilized to compare categorical variables. The Kaplan-Meier approach was utilized to estimate survival probabilities and a log-rank test was applied to evaluate significant differences in overall survival (OS) stratified by respective covariate. Cox regression analysis was utilized to analyze the correlations between prognostic factors and OS or CSS. We carried out a propensity-score matching (PSM) analysis at a 1: 1 ratio between PCCCL patients and patients pathologically confirmed common-type HCC over the same time period from the SEER database, which modulated the differences between PCCCL and common-type HCC group to compare their prognoses. X-tile software was applied to resolve the optimal cutoff levels of prognostic factors and R language 3.5.3 Software with the rms and survival packages was used to determine the prognostic nomogram, concordance index (C-index), and calibration curve. Two tailed *P*\<0.05 was defined to be statistically significant.

Results
=======

Patient characteristics
-----------------------

Our data consisted of a total of 419 qualified patients with PCCCL. Demographic and clinicopathological characteristics of such patients are depicted in [Table 1](#t1-medscimonit-26-e919789){ref-type="table"}. The number of patients who underwent cancer-oriented surgery was 157 patients (37.5%) in the PCCCL group. Chemotherapy was performed for 29.8% of cases, [Supplementary Table 1](#s4-medscimonit-26-e919789){ref-type="supplementary-material"} shows that younger PCCCL patients with larger or remotely metastatic lesions and elevated AFP levels as well as advanced disease stage were prone to receive chemotherapy. Additionally, patients managed by some form of radiotherapy merely accounted for 6.2% of patients. Analogously, as is shown in [Supplementary Table 2](#s5-medscimonit-26-e919789){ref-type="supplementary-material"}, PCCCL patients who were administered with radiotherapy were characterized by larger or metastatic lesions, advanced disease stage and increased AFP levels, compared with those without radiation.

Patient survival
----------------

The mean survival time of such PCCCL patients was 25.6 months (95% confidence interval \[CI\] 22.2--29) ([Figure 1A](#f1-medscimonit-26-e919789){ref-type="fig"}, [Table 2](#t2-medscimonit-26-e919789){ref-type="table"}). The overall 1-year, 3-year, and 5-year survival probability was 59.5%, 39.3%, and 29.9%, respectively ([Table 3](#t3-medscimonit-26-e919789){ref-type="table"}). In an attempt to explore the prognostic difference between PCCCL patients and common-type HCC patients, 419 PCCCL patients were matched with 419 patients who were pathologically diagnosed common-type HCC ranging from 1988 to 2015 (1: 1) in the SEER database. As was revealed in [Supplementary Table 3](#s6-medscimonit-26-e919789){ref-type="supplementary-material"}, there were no statistically significant discrepancies in clinical characteristics after PSM analysis. Concerning clinically prognostic outcomes at PCCCL patients versus their counterparts with common-type HCC, survival curves and log-rank analysis demonstrated no statistically significant difference ([Figure 1B](#f1-medscimonit-26-e919789){ref-type="fig"}).

OS analysis stratified by clinical features was revealed in [Table 2](#t2-medscimonit-26-e919789){ref-type="table"}. The OS of patients was not correlated with age ([Supplementary Figure 1A](#s1-medscimonit-26-e919789){ref-type="supplementary-material"}). Based on SEER summary stage, patients with more advanced disease stage were endowed with a much more unfavorable prognosis, compared with those with localized or regional disease ([Supplementary Figure 1B](#s1-medscimonit-26-e919789){ref-type="supplementary-material"}). Indeed, the 3-year survival rate for patients with localized and regional lesions was 53.3% and 27.3%, respectively, compared with merely 6.1% for patients with distant lesions ([Table 3](#t3-medscimonit-26-e919789){ref-type="table"}). Analogously, the 1-year and 3-year survival rates for patients with TNM I, II, and III stage were 79.8%, 76.1%, 56.5%, and 64.7%, 54.6%, 19.9%, respectively, compared with merely 22.4% and 9.2% in patients with IV stage disease ([Table 3](#t3-medscimonit-26-e919789){ref-type="table"}, [Figure 2A](#f2-medscimonit-26-e919789){ref-type="fig"}). Predictably, both lymph node involvement and remotely metastatic lesions in PCCCL patients were intimately associated with adverse clinical outcomes ([Figure 2B, 2C](#f2-medscimonit-26-e919789){ref-type="fig"}). Enhanced levels of AFP were correlated with significantly diminished mean survival time (22.3 months versus 31.9 months, *P*\<0.01) ([Figure 2D](#f2-medscimonit-26-e919789){ref-type="fig"}). Unexpectedly, the outcome of patients with well or moderately pathologically differentiated tumor was not better than those with poorly differentiated or undifferentiated tumor ([Supplementary Figure 1C](#s1-medscimonit-26-e919789){ref-type="supplementary-material"}), which is deserved to be further discussed. Furthermore, liver fibrosis imposed no significant effect on OS ([Supplementary Figure 1D](#s1-medscimonit-26-e919789){ref-type="supplementary-material"}).

Additionally, cancer-targeted surgery was capable of significantly prolonging survival time and improving clinical effects ([Figure 3A](#f3-medscimonit-26-e919789){ref-type="fig"}). The OS was 47.3 months for patients administered with surgical procedures, which remarkably exceeded the 12.7 months OS of those who did not receive surgery (*P*\<0.001). We also utilized survival curves to compare the efficacy of different surgical categories. As a whole, patients who received a hepatic transplant had a much more satisfactory prognosis than those who underwent local ablation or resection (*P*\<0.01 for both) ([Table 2](#t2-medscimonit-26-e919789){ref-type="table"}, [Figure 3D](#f3-medscimonit-26-e919789){ref-type="fig"}). To eliminate several confounding factors, we performed PSM analysis and thus made two conclusions. That is, patients who received radiotherapy showed no statistically significant differences in OS compared with those without radiotherapy ([Figure 3B](#f3-medscimonit-26-e919789){ref-type="fig"}). Similarly, no significant relationship between chemotherapy and survival benefits was revealed ([Figure 3C](#f3-medscimonit-26-e919789){ref-type="fig"}).

Univariate and multivariate Cox proportional hazard analyses
------------------------------------------------------------

Prognostic factors for OS of PCCCL are depicted in [Tables 2](#t2-medscimonit-26-e919789){ref-type="table"} and [4](#t4-medscimonit-26-e919789){ref-type="table"}. For the univariate analysis ([Table 2](#t2-medscimonit-26-e919789){ref-type="table"}), large lesion size, lymph node invasion, and remotely metastatic lesions, more advanced TNM stage and SEER stage as well as elevated AFP levels were the risk factors associated with unfavorable prognosis, in contrast, to confer surgical treatment to patients had the capacity to effectively boost OS (*P*\<0.05 for all). In addition to TNM stage and SEER stage, additional aforementioned univariate analysis was included in the multivariate Cox analysis. This is because both stages overlapped with tumor size, lymph node invasion, and distant metastases \[[@b18-medscimonit-26-e919789]\]. As was revealed in multivariate Cox analysis ([Table 4](#t4-medscimonit-26-e919789){ref-type="table"}), larger or remotely metastatic lesions in conjunction with increased AFP levels were all independent adverse prognostic factors for PCCCL (*P*\<0.05 for all). Conversely, surgical intervention was sufficient to diminish the risk of death in contrast to non-surgical treatment (HR=0.23, 95% CI 0.17--0.31, *P*\<0.001), indicating that surgical treatment was an independent protective factor for enhanced OS.

Specifically, larger lesions (\>96 mm) exerted a negative impact on the survival time of PCCCL patients ([Figure 4](#f4-medscimonit-26-e919789){ref-type="fig"}, [Table 2](#t2-medscimonit-26-e919789){ref-type="table"}). Moreover, X-tile program demonstrated that 37 mm and 96 mm were the optimal cut-points to predict prognosis for tumor size ([Supplementary Figure 2](#s2-medscimonit-26-e919789){ref-type="supplementary-material"}). In terms of the optimal cut-points, incorporated PCCCL patients could be classified into 3 groups which displayed statistically significant differences in size-associated OS via the Kaplan-Meier curve analysis.

Prognostic nomogram for PCCCL
-----------------------------

In an attempt to predict long-term survival of PCCCL patients, a nomogram was further formulated by incorporating all significant independent indicators for OS identified by the multivariate analyses. As was illustrated in [Figure 5](#f5-medscimonit-26-e919789){ref-type="fig"}, surgery and tumor size made the greatest contributions to clinical prognosis, followed by metastasis category and AFP levels. The C-index for OS prediction was 0.761, and thereby the predictive accuracy of such nomogram was relatively satisfactory. The calibration curves for the OS probability of 1-year, 3-year or 5-year in PCCCL patients cohort displayed an optimal consistency between the prediction via nomogram and practical surveillance ([Supplementary Figure 3](#s3-medscimonit-26-e919789){ref-type="supplementary-material"}).

Discussion
==========

PCCCL is a specific and uncommon histological type of HCC, characterized with clear cells embracing glycogen decorated in tubular, papillary, and solid designs \[[@b19-medscimonit-26-e919789]\], whose low incidence in clinical practice has imposed restrictions on our comprehensive understanding of its clinicopathological and prognostic characteristics. In our study, we depicted the clinicopathological features and demonstrated factors influencing OS of 419 PCCCL patients extracted from the SEER database from 1988 to 2015. Additionally, we formulated a prognostic nomogram with satisfactory accuracy for intuitively predicting 1-year, 3-year, and 5-year survival rate of PCCCL patients.

Our study revealed that the age of patients diagnosed with PCCCL ranged from 52 to 76 years old and a large proportion of patients included in the overall cohort were white (65.6%, 275 of 419), which was roughly consistent to the results of the Jernigan et al. study \[[@b20-medscimonit-26-e919789]\]. There was a male preponderance collectively, accounting for 64.0% of total patients, which was a little lower than 69.6% reported in a literature review \[[@b21-medscimonit-26-e919789]\]. Patients had larger tumor size (\>96 mm) in the present study in comparison with the previous report representing a tumor diameter of 50 mm, which was correlated with more aggressive PCCCL, respectively \[[@b22-medscimonit-26-e919789]\]. Of patients with PCCCL in the cohort with recorded pathological differentiation grade, tumor with moderate differentiation occupied a maximal proportion (27.0%, 113 of 419), which corresponded to the description in additional studies \[[@b4-medscimonit-26-e919789],[@b16-medscimonit-26-e919789],[@b20-medscimonit-26-e919789]\]. Of those who have undergone lymph node examinations, lymph node metastases were not usual, representing merely 4.5%, which was also reflected in the TNM pathologic stage, with more likely to be stage I or II, indicating the relatively indolent biology of PCCCL. Accumulating evidence from previous sporadic cases also supported the notion that the majority of PCCCL cases were moderately differentiated, concomitant with comparatively low metastatic potential \[[@b4-medscimonit-26-e919789],[@b20-medscimonit-26-e919789],[@b23-medscimonit-26-e919789]\]. However, a retrospective clinical study showed that up to 18.75% of patients displayed lymph node metastasis and thus 65.6% of them were pathologically diagnosed at TNM stage III or IV through analyzing 64 patients with PCCCL in their hospital \[[@b5-medscimonit-26-e919789]\]. A large proportion of patients with PCCCL were accompanied by elevated AFP levels, which were in accordance with additional researches results \[[@b4-medscimonit-26-e919789],[@b7-medscimonit-26-e919789],[@b23-medscimonit-26-e919789]\]. Notably, severe hepatic fibrosis, classically considered as one of indicators of liver inflammation, did not account for a higher proportion in PCCCL patients. Nevertheless, some previous studies revealed that the majority of patients with PCCCL were primarily on the basis of hepatic cirrhosis that was independent risk factors for OS of PCCCL \[[@b7-medscimonit-26-e919789],[@b8-medscimonit-26-e919789],[@b23-medscimonit-26-e919789],[@b24-medscimonit-26-e919789]\].

In the current report, there was no statistically significant discrepancy in prognosis between PCCCL patients and those with common-type HCC. Nevertheless, the prognosis of PCCCL patients is being debated. Multiple studies showed that PCCCL had a more favorable prognosis than additional HCC \[[@b5-medscimonit-26-e919789],[@b9-medscimonit-26-e919789],[@b25-medscimonit-26-e919789],[@b26-medscimonit-26-e919789]\]. A study demonstrated that the clinical outcome seemed to be better in PCCCL patients than their common-type counterparts, and the survival time enhanced with an accumulating apportion of clear cells \[[@b9-medscimonit-26-e919789]\]. Oppositely, some studies revealed that the prognosis of PCCCL patients was analogous to that of those with common-type HCC and potentially even worse \[[@b12-medscimonit-26-e919789]--[@b14-medscimonit-26-e919789]\]. Based on our univariate analysis, advanced TNM and SEER summary disease stages were both correlated with adverse prognosis in PCCCL patients. Indeed, OS of PCCCL patients with TNM-I was 36.9 months, compared with merely 14.1 months for patients with TNM-IV. Intriguingly, the present study, unlike the results from additional cohort studies that pathological differentiation degree was one of the valuable prognostic factors in PCCCL, seemed to display no statistically significant dissimilarity in OS in accordance with the pathological differentiation conditions in this tumor. Such inconsistency was supposed to reflect the relatively small sample size and the actuality that cases were primarily composed of tumor with well or moderately pathological differentiation \[[@b5-medscimonit-26-e919789],[@b22-medscimonit-26-e919789]\]. Notably, lymph node metastasis was also a pivotal risk factor in PCCCL in univariate analysis, which would not influence patient OS after modulating for additional variables in multivariate analysis. The reason behind this phenomenon potentially is that our study could acquire very few PCCCL cases with lymph node metastasis from the SEER database. Cox multivariate analysis indicated that patients with larger lesions (\> 96 mm) and distant dissemination as well as elevated AFP levels were related to unsatisfactory survival time. Therefore, early detection and surgical treatment may be of great essential to reap optimal outcomes for PCCCL patients.

Cox multivariate analysis indicated that surgical treatment was regarded as the most promising therapeutic intervention to fulfill satisfactory outcomes and reduced the risk of death of PCCCL patients. The 5-year survival rate for patients with PCCCL would reach up to 57.3% if patients undergo surgery timely. Indeed, a prior study also showed that 1-year and 3-year survival rates of all 13 patients managed by surgical resection was 76.5% and 47.1%, respectively, and the longest survival time was up to 97 months \[[@b15-medscimonit-26-e919789]\]. Similarly, a 55-year-old male patient with retroperitoneal and intrahepatic metastasis of PCCCL was performed with surgical resection and transcatheter arterial chemoembolization (TACE), without any recurrence and metastasis during 16 months follow-up \[[@b16-medscimonit-26-e919789]\]. Theoretically, PCCCL is characterized by relatively tardy progress, better tumor differentiation, easier pseudo-capsule formation, lower vascular invasion and lymph node metastasis, which all make great contributions to its high resectability rate \[[@b5-medscimonit-26-e919789]\]. Notably, Liu et al. revealed a much higher formation rate of pseudo-capsule in patients with PCCCL than in non-PCCCL HCC patients (75% versus 49.6%, *P*\<0.05) \[[@b8-medscimonit-26-e919789]\]. Such pseudo-capsule is primarily composed of peritumoral hepatic sinusoids with or without fibrosis \[[@b7-medscimonit-26-e919789]\]. With regard to surgical strategies, we found that liver transplantation had the first-rank clinical outcome, followed by surgical resection and local tumor destruction, and surgical resection was still the most momentous and routine tactic to achieve long-term survival for most HCC patients, which was backed up by other studies \[[@b20-medscimonit-26-e919789],[@b27-medscimonit-26-e919789]\]. Currently, literature is confined to researches utilizing surgical resection as the central therapeutic intervention for PCCCL and there are merely several cases of PCCCL that are managed by hepatic transplantation \[[@b28-medscimonit-26-e919789]\]. On account of the rarity of PCCCL cases, confined clinical knowledge is accessible to non-surgical manipulations, including radiofrequency ablation, TACE, percutaneous ethanol injection, or sorafenib as principal intervention measures \[[@b7-medscimonit-26-e919789]\]. For example, in another retrospective study, of those managed by surgical therapy, 81.9% of patients received surgical resection, 16% of them underwent orthotopic liver transplant, and 0.21% of cases were administered with local ablative procedures. And transplantation conferred an obvious and preponderant survival advantage over resection or local ablation \[[@b20-medscimonit-26-e919789]\].

Currently, the efficacy of chemotherapy or radiotherapy as primary intervention or as adjuvant treatment for the prognosis of patient with PCCCL still remains controversial \[[@b16-medscimonit-26-e919789]\]. Our study revealed that both chemotherapy and radiotherapy failed to be considered as prognostic factors and thus were not sufficient to accomplish long-term survival, which potentially was partly attributed to worse physical status of PCCCL patients receiving radiation or chemotherapy. Additionally, a report considered that postoperative adjuvant chemotherapy with calcium folinate and tegafur resulted in no significant improvement in the survival time of PCCCL patients \[[@b5-medscimonit-26-e919789]\]. Similarly, 3 other case reports regarding unresectable PCCCL patients also approved the opinion that PCCCL was not susceptive to chemotherapy and radiotherapy, exhibiting undesirable survival time \[[@b12-medscimonit-26-e919789],[@b16-medscimonit-26-e919789],[@b29-medscimonit-26-e919789]\]. Intriguingly, in 2019, a case report firstly discovered that sunitinib-based systematic therapy clinically cured a male PCCCL patient with multiple metastatic lesions \[[@b30-medscimonit-26-e919789]\]. However, as this is merely a case study, the evidence level of such treatment is extremely finite. Whether chemotherapy or radiotherapy exerts conducive effects on the prognosis of PCCCL patients are needed for further investigation.

Notably, in our current study, an exploratory analysis of a rare type of HCC embraced the largest number of PCCCL patients to date, which was accomplished through utilizing large multi-institution databases. PSM analysis further potentiated the credibility of our findings. To our knowledge, we formulated the first nomogram to predict the survival of PCCCL patients, which depended on the SEER database with long-term follow-up. Physicians and patients will have the capacity to produce individualized survival predictions via such an available scoring system. However, it is pivotal to avert overfitting of the model and determined generalizability through validating the nomogram \[[@b3-medscimonit-26-e919789]\].

Nevertheless, it should be mentioned that this study had several limitations which are intrinsic to any retrospective analyses of SEER database. The SEER database failed to confer the comprehensive data concerning the risk factors for tumorigenesis, such as HCV infection, liver cirrhosis \[[@b6-medscimonit-26-e919789]\]. The SEER database also does not provide the momentous additional evaluation indicators to allow for convincing reflection on the severity degree of PCCCL, such as Child-Pugh classification, large vascular invasion or not, and aneuploid deoxyribonucleic acid content \[[@b5-medscimonit-26-e919789],[@b15-medscimonit-26-e919789],[@b31-medscimonit-26-e919789]\]. Both higher proportion of clear cells and capsule formation have been associated with the desirable outcome of the management \[[@b4-medscimonit-26-e919789],[@b22-medscimonit-26-e919789]\], which should be included in this database and thus potentially validate and optimize our nomogram. Indeed, Chen et al. retrospectively analyzed that proportion of clear cells ≥70% indicated better prognosis \[[@b22-medscimonit-26-e919789]\]. Furthermore, specified risk factors regarding PCCCL recurrence are not documented, which limits our capacity to depict therapies patterns administrated after recurrence such as the accurate chemotherapies delivered or radiation schedules. Thirdly, the SEER database merely confers diseases occurring among American population, and additional countries with high incidence of PCCCL fail to be incorporated for integral analysis. Ultimately, the study is retrospective and additional prospective trials are required to investigate to validate a precise conclusion.

Conclusions
===========

Collectively, our study incorporated the comparatively large national sample to reveal certain significant factors influencing PCCCL prognosis. Specifically, larger tumor size, distant metastases, and elevated AFP levels were considered as unfavorably prognostic factors for PCCCL. Oppositely, surgical intervention tended to confer a significant and superior survival advantage to patients, while PCCCL was non-sensitive to chemotherapy and radical therapy. We also formulated an intuitionistic nomogram to readily predict long-term survival, which may be conducive to further facilitating the establishment of clinical management strategies and prospective researches in such patient population.

Supplementary Data
==================

###### 

OS for patients with PCCCL stratified by (**A**) age. (**B**) different SEER summary stages. (**C**) pathological differentiation grade. (**D**) liver fibrosis score. OS -- overall survival; PCCCL -- primary clear cell carcinoma of the liver.

###### 

The optimal cut-off of tumor size in PCCCL patients. PCCCL -- primary clear cell carcinoma of the liver.

###### 

The calibration plots for predicting PCCCL patient survival at (**A**) 1 years and (**B**) 3 years, and (**C**) 5 years. PCCCL -- primary clear cell carcinoma of the liver.

###### 

Patient features by chemotherapy.

  Characteristics         No chemo- therapy   Chemo- therapy   P-value
  ----------------------- ------------------- ---------------- ---------
  Total                   294                 125              
  Age (years)             65.7±12.3           61.4±11.8        \<0.001
  Gender                                                       0.368
   Female                 110                 41               
   Male                   184                 84               
  Race                                                         0.852
   White                  194                 81               
   Black                  32                  16               
   Unknown                68                  28               
  Marital status                                               0.1
   Married                228                 104              
   Single                 58                  15               
   Unknown                8                   6                
  Grade                                                        0.91
   Well; I                43                  20               
   Moderately; II         79                  34               
   Poorly; III            25                  13               
   Undifferentiated; IV   4                   2                
   Unknown                143                 56               
  Tumor stage                                                  0.03
   T1                     128                 41               
   T2                     40                  20               
   T3                     43                  30               
   T4                     63                  31               
   Unknown                20                  3                
  Lymph node metastases                                        0.68
   N0                     226                 100              
   N1                     13                  6                
   Unknown                55                  19               
  Distant metastases                                           0.07
   M0                     229                 96               
   M1                     47                  27               
   Unknown                18                  2                
  Summary stage                                                \<0.01
   Localized              169                 57               
   Regional               60                  39               
   Distance               47                  27               
   Unknown                18                  2                
  TNM stage                                                    \<0.01
   I                      108                 29               
   II                     34                  17               
   III                    51                  39               
   IV                     47                  27               
   Unknown                54                  13               
  AFP level                                                    \<0.001
   Elevated               165                 94               
   Normal                 126                 31               
   Unknown                3                   0                
  Surgery                                                      \<0.001
   No                     165                 94               
   Yes                    126                 31               
   Unknown                3                   0                
  Radiation                                                    0.01
   No                     282                 111              
   Yes                    12                  14               

###### 

Patient features by radiation.

  Characteristics         No radiation   Radiation   P-value
  ----------------------- -------------- ----------- ---------
  Total                   393            26          
  Age (years)             64.6±12.2      60.7±13.7   0.16
  Gender                                             0.56
   Female                 143            250         
   Male                   8              18          
  Race                                               0.58
   White                  255            20          
   Black                  45             2           
   Unknown                92             4           
  Marital status                                     0.23
   Married                311            21          
   Single                 70             3           
   Unknown                12             2           
  Grade                                              0.29
   Well; I                61             2           
   Moderately; II         108            5           
   Poorly; III            33             5           
   Undifferentiated; IV   6              0           
   Unknown                185            14          
  Tumor stage                                        0.37
   T1                     161            8           
   T2                     56             4           
   T3                     70             3           
   T4                     86             8           
   Unknown                20             3           
  Lymph node metastases                              0.43
   N0                     305            21          
   N1                     17             2           
   Unknown                71             3           
  Distant metastases                                 \<0.001
   M0                     313            12          
   M1                     62             12          
   Unknown                18             2           
  Summary stage                                      \<0.001
   Localized              222            4           
   Regional               91             8           
   Distance               62             12          
   Unknown                18             2           
  TNM stage                                          \<0.001
   I                      133            4           
   II                     49             2           
   III                    85             5           
   IV                     62             12          
   Unknown                64             3           
  AFP level                                          0.01
   Elevated               173            18          
   Normal                 62             0           
   Unknown                158            8           
  Surgery                                            0.1
   No                     241            18          
   Yes                    150            7           
   Unknown                2              1           
  Radiation                                          0.011
   No                     282            111         
   Yes                    12             14          

###### 

Patient features for PCCCL and common-type HCC after PSM analysis.

  Characteristics         PCCCL       Common-type hepato-cellular   P-value
  ----------------------- ----------- ----------------------------- ---------
  Total                   419         419                           
  Age (years)             64.4±12.3   64.9±12.0                     0.50
  Gender                                                            0.38
   Female                 151         139                           
   Male                   268         280                           
  Race                                                              0\. 81
   White                  282         282                           
   Black                  48          49                            
   Unknown                96          88                            
  Marital status                                                    0.63
   Married                332         343                           
   Single                 73          64                            
   Unknown                14          12                            
  Grade                                                             0.95
   Well; I                63          70                            
   Moderately; II         113         115                           
   Poorly; III            38          34                            
   Undifferentiated; IV   6           6                             
   Unknown                6           194                           
  Tumor stage                                                       0.89
   T1                     168         156                           
   T2                     60          62                            
   T3                     74          78                            
   T4                     94          95                            
   Unknown                23          28                            
  Lymph node metastases                                             
   N0                     326         316                           
   N1                     19          17                            
   Unknown                74          86                            
  Distant metastases                                                0.73
   M0                     325         316                           
   M1                     74          83                            
   Unknown                20          20                            
  AFP level                                                         0.87
   Elevated               191         184                           
   Normal                 62          66                            
   Unknown                166         169                           
  Surgery (Y/N)                                                     0.58
   No                     259         264                           
   Yes                    157         154                           
   Unknown                3           1                             
  Radiation                                                         0.36
   No                     393         395                           
   Yes                    26          24                            
  Chemotherapy                                                      0.48
   No                     294         306                           
   Yes                    125         113                           

**Source of support:** This work was supported by the National Natural Science Foundation of China \[81872473 (P.Cao)\]; the Hunan Province Science and Technology plan \[2017SK2052 (P.Cao)\]

**Conflicts of interest**

None.

PCCCL

:   primary clear cell carcinoma of the liver

HCC

:   hepatocellular carcinoma

SEER

:   Surveillance, Epidemiology and End Results

OS

:   overall survival

CI

:   confidence interval

AFP

:   alpha-fetoprotein

HR

:   hazard ratio

HCV

:   hepatitis C virus

PSM

:   propensity-score matching

C-index

:   concordance index

EMA

:   epithelial membrane antigen

TACE

:   transcatheter arterial chemoembolization

![OS for patients with PCCCL. (**A**) OS for 419 patients with PCCCL. (**B**) OS comparison between PCCCL and common type. OS -- overall survival; PCCCL -- primary clear cell carcinoma of the liver; HCC -- hepatocellular carcinoma; PSM -- propensity-score matching.](medscimonit-26-e919789-g001){#f1-medscimonit-26-e919789}

![OS for patients with PCCCL stratified by (**A**) different TNM stages. (**B**) Lymph node metastases. (**C**) Distant metastases. (**D**) AFP levels. OS -- overall survival; PCCCL -- primary clear cell carcinoma of the liver; AFP -- alpha-fetoprotein.](medscimonit-26-e919789-g002){#f2-medscimonit-26-e919789}

![OS for patients with PCCCL stratified by (**A**) surgery. (**B**) Radiation. (**C**) Chemotherapy. (**D**) Different surgical strategies. OS -- overall survival; PCCCL -- primary clear cell carcinoma of the liver.](medscimonit-26-e919789-g003){#f3-medscimonit-26-e919789}

![OS for patients with PCCCL stratified by tumor size. OS -- overall survival; PCCCL -- primary clear cell carcinoma of the liver.\
PCCCL -- primary clear cell carcinoma of the liver; AFP -- alpha-fetoprotein; CI -- confidence interval; HR -- hazard ratio.](medscimonit-26-e919789-g004){#f4-medscimonit-26-e919789}

![Prognostic nomogram estimated by clinical features for the overall 1-year, 3-year, and 5-year survival rate in PCCCL patients. PCCCL -- primary clear cell carcinoma of the liver.](medscimonit-26-e919789-g005){#f5-medscimonit-26-e919789}

###### 

Characteristics of 419 patients with PCCCL.

  Characteristics              Number      Percent
  ---------------------------- ----------- ---------
  Total                        419         
  Age (years)                  64.4±12.3   
   ≤60                         165         31.8%
   61--70                      117         22.5%
   \>70                        137         26.4%
  Gender                                   
   Female                      151         36.0%
   Male                        268         64.0%
  Race                                     
   White                       275         65.6%
   Black                       48          11.5%
   Unknown                     96          22.9%
  Marital status                           
   Married                     332         79.2%
   Single                      73          17.4%
   Unknown                     14          3.3%
  Grade                                    
   Well; I                     63          15.0%
   Moderately; II              113         27.0%
   Poorly; III                 38          9.1%
   Undifferentiated; IV        6           1.4%
   Unknown                     199         47.5%
  Tumor stage                              
   T1                          168         40.1%
   T2                          60          14.3%
   T3                          74          17.7%
   T4                          94          22.4%
   Unknown                     23          5.5%
  Lymph node metastases                    
   N0                          326         77.8%
   N1                          19          4.5%
   Unknown                     74          17.7%
  Distant metastases                       
   M0                          325         77.6%
   M1                          74          17.7%
   Unknown                     20          4.8%
  Summary stage                            
   Localized                   226         53.9%
   Regional                    99          23.6%
   Distance                    74          17.7%
   Unknown                     20          4.8%
  TNM stage                                
   I                           136         32.5%
   II                          51          12.2%
   III                         91          21.7%
   IV                          74          17.7%
   Unknown                     67          16.0%
  AFP level                                
   Elevated                    191         45.6%
   Normal                      62          14.8%
   Unknown                     166         39.6%
  Fibrosis score                           
   0--4                        42          10.0%
   5--6                        45          10.7%
   Unknown                     332         79.2%
  Surgery type                             
   Local ablation              28          17.8%
   Resection                   115         73.2%
   Transplant                  13          8.3%
   Surgery with unknown type   1           0.6%
  Surgery                                  
   No                          259         61.8%
   Yes                         157         37.5%
   Unknown                     3           0.7%
  Radiation                                
   No                          393         93.8%
   Yes                         26          6.2%
  Chemotherapy                             
   No                          294         70.2%
   Yes                         125         29.8%

PCCCL -- primary clear cell carcinoma of the liver; AFP -- alpha-fetoprotein.

###### 

Overall survival stratified by clinical features and univariate Cox proportional hazard analyses for PCCCL patients.

  Variables                    Mean survival months   95% CI        Univariate analysis   
  ---------------------------- ---------------------- ------------- --------------------- ---------
  Total                        25.6                   22.2--29                            
  Age (years)                                                                             
   ≤60                         27.7                   21.6--33.8    Ref                   
   61--70                      30.5                   23.6--37.5    0.93 (0.68--1.27)     0.665
   \>70                        18.8                   14.5--23.2    1.22 (0.9--1.64)      0.200
  Gender                                                                                  
   Female                      33.1                   22.5--33.1    Ref                   
   Male                        36.6                   20--28.8      1.04 (0.8--1.34)      0.793
  Race                                                                                    
   White                       25.6                   21.4--29.9    Ref                   
   Black                       21.3                   12.1--30.6    1.14 (0.77--1.69)     0.517
  Marital status                                                                          
   Married                     27.1                   23.1--31.1    Ref                   
   Single                      19.6                   13.4--25.8    1.33 (0.97--1.83)     0.079
  Grade                                                                                   
   Well                        31.6                   22.3--40.8    Ref                   
   Moderately                  31.3                   24.8--37.8    0.82 (0.55--1.24)     0.358
   Poor and undifferentiated   34.5                   20.5--48.5    0.96 (0.58--1.59)     0.872
  Tumor stage                                                                             
   T1                          36.9                   30.5--43.3    Ref                   
   T2                          32.8                   22.3--43.3    1.08 (0.7--1.68)      0.723
   T3                          12.6                   8.7--16.5     3.2 (2.25--4.56)      \<0.001
   T4                          14.1                   9.4--18.8     3.01 (2.16--4.19)     \<0.001
  Tumor size                                                                              
   ≤37 mm                      49.2                   39.7--58.7    Ref                   
   37--96 mm                   28.7                   23.1--34.4    2.7 (1.79--4.12)      \<0.001
   \>96 mm                     15.1                   10.1--20.1    5.28 (3.37--8.28)     \<0.001
  Lymph node metastases                                                                   
   N0                          28.4                   24.4--32.4    Ref                   
   N1                          8.1                    3.8--12.3     2.63 (1.51--4.58)     \<0.001
  Distant metastases                                                                      
   M0                          30.4                   26.2--34.6    Ref                   
   M1                          7.7                    5.1--10.3     3.25 (2.38--4.45)     \<0.001
  Summary stage                                                                           
   Localized                   35.7                   30.5--41      Ref                   
   Regional                    18.3                   12.4--24.2    2.11 (1.55--2.88)     \<0.001
   Distance                    7.7                    5.1--10.3     4.17 (2.98--5.84)     \<0.001
  TNM stage                                                                               
   I                           39.9                   32.9--46.9    Ref                   
   II                          35.7                   23.7--47.7    1.04 (0.62--1.73)     0.882
   III                         17.4                   12.3--22.5    3.03 (2.11--4.36)     \<0.001
   IV                          7.7                    5.1--10.3     5.73 (3.88--8.46)     \<0.001
  AFP level                                                                               
   Elevated                    22.3                   17.8--26.7    Ref                   
   Normal                      31.9                   23.9--39.9    0.51 (0.34--0.78)     \<0.001
  Fibrosis score                                                                          
   0--4                        28.2                   20.3--36.2                          
   5--6                        33.6                   21.7--45.4    1.09 (0.61--1.95)     0.790
  Surgery type                                                                            
   Local ablation              33                     22.8--43.3    Ref                   
   Resection                   45.2                   37.4--53.1    0.99 (05--1.97)       0.980
   Transplant                  100.2                  65.0--135.4   0.1 (0.01--0.77)      0.02
  Surgery                                                                                 
   No                          12.7                   10.3--15      Ref                   
   Yes                         47.3                   40.3--54.4    0.23 (0.17--0.31)     \<0.001
  Radiation                                                                               
   No                          26.3                   22.7--29.9    Ref                   
   Yes                         15.7                   9.2--22.3     1.4 (0.87--2.27)      0.169
  Chemotherapy                                                                            
   No                          26.1                   21.7--30.4    Ref                   
   Yes                         24.6                   19.3--29.8    1.11 (0.85--1.45)     0.441

PCCCL -- primary clear cell carcinoma of the liver; AFP -- alpha-fetoprotein; CI -- confidence interval; HR -- hazard ratio.

###### 

1-year, 3-year, and 5-year survival rates stratified by clinical features for PCCCL patients.

  Characteristics              Cancer specific survival                                              
  ---------------------------- -------------------------- ------------ ------- ------------ -------- ------------
  Total                        0.595                      0.55--0.65   0.393   0.34--0.45   0.299    0.25--0.36
  Age (years)                                                                                        
   ≤60                         0.565                      0.49--0.65   0.417   0.34--0.51   0.348    0.27--0.45
   61--70                      0.656                      0.57--0.75   0.434   0.35--0.55   0.327    0.24--0.45
   \>70                        0.574                      0.49--0.67   0.312   0.23--0.42   0.219    0.14--0.35
  Gender                                                                                             
   Female                      0.646                      0.57--0.73   0.377   0.3--0.47    0.293    0.22--0.39
   Male                        0.565                      0.51--0.63   0.408   0.35--0.48   0.304    0.24--0.39
  Race                                                                                               
   White                       0.591                      0.53--0.66   0.383   0.32--0.46   0.293    0.23--0.37
   Black                       0.468                      0.34--0.65   0.348   0.23--0.54   \\       \\
  Marital status                                                                                     
   Married                     0.659                      0.6--0.73    0.460   0.39--0.54   0.395    0.33--0.48
   Single                      0.499                      0.42--0.59   0.279   0.21--0.37   0.161    0.1--0.26
  Grade                                                                                              
   Well                        0.654                      0.55--0.79   0.450   0.33--0.61   0.323    0.21--0.51
   Moderately                  0.720                      0.64--0.81   0.499   0.4--0.62    0.393    0.3--0.52
   Poor and undifferentiated   0.725                      0.6--0.88    0.356   0.23--0.55   \\       \\
  Tumor stage                                                                                        
   T1                          0.746                      0.68--0.82   0.588   0.51--0.68   0.47     0.39--0.57
   T2                          0.706                      0.59--0.84   0.470   0.34--0.65   \\       \\
   T3                          0.422                      0.32--0.57   0.150   0.08--0.29   0.0501   0.01--0.19
   T4                          0.400                      0.31--0.52   0.170   0.1--0.29    0.0969   0.04--0.26
  Tumor size                                                                                         
   ≤37 mm                      0.928                      0.87--0.99   0.781   0.69--0.88   0.633    0.52--0.77
   37--96 mm                   0.646                      0.57--0.73   0.402   0.32--0.5    0.281    0.21--0.38
   \>96 mm                     0.397                      0.3--0.53    0.147   0.08--0.28   \\       \\
  Lymph node metastases                                                                              
   N0                          0.659                      0.61--0.72   0.442   0.39--0.51   0.34     0.28--0.41
   N1                          0.240                      0.1--0.56    \\      \\           \\       \\
  Distant metastases                                                                                 
   M0                          0.672                      0.62--0.73   0.460   0.4--0.53    0.354    0.3--0.43
   M1                          0.242                      0.16--0.38   0.061   0.02--0.2    \\       \\
  Summary stage                                                                                      
   Localized                   0.741                      0.68--0.8    0.533   0.47--0.61   0.425    0.35--0.51
   Regional                    0.498                      0.4--0.62    0.273   0.19--0.4    0.172    0.1--0.31
   Distance                    0.224                      0.14--0.36   0.061   0.02--0.2    \\       \\
  TNM stage                                                                                          
   I                           0.798                      0.73--0.87   0.647   0.56--0.74   0.516    0.42--0.63
   II                          0.761                      0.65--0.9    0.546   0.4--0.74    \\       \\
   III                         0.565                      0.47--0.69   0.199   0.12--0.33   0.083    0.03--0.22
   IV                          0.224                      0.14--0.36   0.092   0.04--0.22   \\       \\
  AFP level                                                                                          
   Elevated                    0.535                      0.47--0.62   0.315   0.25--0.4    0.272    0.21--0.36
   Normal                      0.803                      0.7--0.92    0.612   0.48--0.78   0.386    0.25--0.61
  Surgery type                                                                                       
   Local ablation              0.841                      0.71--1      0.725   0.55--0.95   \\       \\
   Resection                   0.854                      0.79--0.93   0.627   0.53--0.74   0.481    0.38--0.61
   Transplant                  0.873                      0.75--1      \\      \\           \\       \\
  Surgery (Y/N)                                                                                      
   No                          0.430                      0.37--0.5    0.192   0.14--0.26   0.1176   0.07--0.19
   Yes                         0.850                      0.79--0.91   0.681   0.61--0.77   0.573    0.49--0.67
  Radiation                                                                                          
   No                          0.600                      0.55--0.65   0.403   0.35--0.46   0.316    0.26--0.38
   Yes                         0.523                      0.36--0.76   \\      \\           \\       \\
  Chemotherapy                                                                                       
   No                          0.562                      0.51--0.63   0.434   0.38--0.5    0.349    0.29--0.42
   Yes                         0.667                      0.59--0.76   0.310   0.23--0.42   0.234    0.16--0.35

PCCCL -- primary clear cell carcinoma of the liver.

###### 

Multivariate Cox proportional hazard analyses of clinical features for overall survival rates in PCCCL patients.

  Variables               Multivariate analysis   
  ----------------------- ----------------------- ---------
  Tumor size                                      
   ≤37 mm                 Ref                     
   37--96 mm              2.54 (1.66--3.89)       \<0.001
   \>96 mm                4.56 (2.86--7.29)       \<0.001
  Lymph node metastases                           
   N0                     Ref                     
   N1                     1.32 (0.73--2.37)       0.361
  Distant metastases                              
   M0                     Ref                     
   M1                     1.45 (1.02--2.06)       0.038
  AFP level                                       
   Elevated               Ref                     
   Normal                 0.57 (0.37--0.88)       0.010
  Surgery                                         
   No                     Ref                     
   Yes                    0.29 (0.21--0.4)        \<0.001
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